

Shoichi Mizuno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/636236/publications.pdf>

Version: 2024-02-01

12
papers

332
citations

1163117

8
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

487
citing authors

#	ARTICLE	IF	CITATIONS
1	Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. <i>Cancer Science</i> , 2022, , .	3.9	3
2	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 334-342.	3.9	13
3	Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 2736-2746.	3.9	12
4	Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. <i>Cancer Science</i> , 2020, 111, 2747-2759.	3.9	19
5	Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radical surgery. <i>Oncology Letters</i> , 2020, 19, 2657-2666.	1.8	9
6	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3049-3060.	3.9	20
7	Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. <i>Cancer Science</i> , 2019, 110, 1842-1852.	3.9	9
8	Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. <i>Scientific Reports</i> , 2019, 9, 5925.	3.3	6
9	Efficacy of the NCCV Cocktail vaccine for refractory pediatric solid tumors: A phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3650-3662.	3.9	8
10	Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. <i>Oncolmmunology</i> , 2018, 7, e1377872.	4.6	39
11	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1346764.	4.6	69
12	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2016, 5, e1129483.	4.6	125